|
|
|
|
Methyltransferases
Immunogen: A synthetic peptide corresponding to aa 152-164, GLLQRRRKWRSQL.
Immunogen: Synthetic peptide: C-GLLQRRRKWRSQL conjugated to KLH, corresponding to amino acids 152-164 of human DNMT 3L.
|
|
|
Apoptosis Caspase
Immunogen: Synthetic peptide (PEHKTSDSTFLVFMSHGIREG) corresponding to amino acids 129-152 of human Caspase-1, coupled to KLH.
Immunogen:-- Synthetic peptide (PEHKTSDSTFLVFMSHGIREG) corresponding to amino acids 129-152 of human Caspase-1, coupled to KLH.
|
|
|
Serologicals - SEC Filings
- xsideNav ul li.test { width:130px; background-image:url(/images/menu/right-Dblue.gif); background-repeat: no-repeat; background-position:right; } Overview Stock Information Corporate Governance FAQs Financial Information Financial Schedules #content { padding: 10px 15px 35px 5px;} #content table { font-size:12px; }.modGovTtl { font-size:13px; font-weight:bold; }.modGovSubTtl { font...
duplicates:
http://WWW.SEROLOGICALS.COM/investors.asp?c=113258&p=irol-secText&TEXT=aHR0cDovL2NjYm4uMTBrd2l6YXJkLmNvbS94bWwvZmlsaW5nLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MjYxODg2MyZkb2M9Mw==
|
|
|
Serologicals - SEC Filings
CONTACT: Serologicals Corporation, Atlanta Bud Ingalls, 678-728-2115 or Craig Brown, 678-728-2117 - ---Previous Page -|- Next Page--- Our Company |- Investors |- Partners |- News & Events |- Contact Us |- For Job Seekers For Scientists |- Serologicals Worldwide |- FAQs Serologicals Corporation 2006 - About Serologicals Our Companies Products and Services Research Research Overview...
|
|
|
Serologicals - SEC Filings
CONTACT: Serologicals Corporation, Atlanta Bud Ingalls, 678-728-2115 or Craig Brown, 678-728-2117 Page 1 ---Previous Page -|- Next Page--- Our Company |- Investors |- Partners |- News & Events |- Contact Us |- For Job Seekers For Scientists |- Serologicals Worldwide |- FAQs Serologicals Corporation 2006 - About Serologicals Our Companies Products and Services Research Research...
|
|
|
Serologicals - SEC Filings
- xsideNav ul li.test { width:130px; background-image:url(/images/menu/right-Dblue.gif); background-repeat: no-repeat; background-position:right; } Overview Stock Information Corporate Governance FAQs Financial Information Financial Schedules #content { padding: 10px 15px 35px 5px;} #content table { font-size:12px; }.modGovTtl { font-size:13px; font-weight:bold; }.modGovSubTtl { font...
duplicates:
http://WWW.SEROLOGICALS.COM/investors.asp?c=113258&p=irol-secText&TEXT=aHR0cDovL2NjYm4uMTBrd2l6YXJkLmNvbS94bWwvZmlsaW5nLnhtbD9yZXBvPXRlbmsmaXBhZ2U9Mjc0MTI4NCZkb2M9Mw==
|
|
|
Serologicals - SEC Filings
SEROLOGICALS CORPORATION Financial Highlights (in thousands, except share and per share amounts) CONSOLIDATED STATEMENTS OF INCOME First Quarter Ended March 28, 2004 and March 30, 2003 (Unaudited) Quarter Ended ----------------------- March 28, March 30, 2004 2003 ----------- ----------- Net sales $36,504 $21,983 Costs and expenses: Cost of sales 17,034 10,214 Selling, general and...
|
|
|
Serologicals - SEC Filings
SEROLOGICALS CORPORATION Financial Highlights (in thousands, except share and per share amounts) CONSOLIDATED STATEMENTS OF INCOME First Quarter Ended March 28, 2004 and March 30, 2003 (Unaudited) Quarter Ended ----------------------- March 28, March 30, 2004 2003 ----------- ----------- Net sales $36,504 $21,983 Costs and expenses: Cost of sales 17,034 10,214 Selling, general and...
|
|
|
Serologicals - SEC Filings
Exhibits and Reports on Form 8-K SIGNATURES - ---Previous Page -|- Next Page--- Our Company |- Investors |- Partners |- News & Events |- Contact Us |- For Job Seekers For Scientists |- Serologicals Worldwide |- FAQs Serologicals Corporation 2006 - About Serologicals Our Companies Products and Services Research Research Overview Enzymes and Assays Stem Cell Products Biomarkers &...
|
|
|
Serologicals - SEC Filings
- xsideNav ul li.test { width:130px; background-image:url(/images/menu/right-Dblue.gif); background-repeat: no-repeat; background-position:right; } Overview Stock Information Corporate Governance FAQs Financial Information Financial Schedules #content { padding: 10px 15px 35px 5px;} #content table { font-size:12px; }.modGovTtl { font-size:13px; font-weight:bold; }.modGovSubTtl { font...
duplicates:
http://WWW.SEROLOGICALS.COM/investors.asp?c=113258&p=irol-secText&TEXT=aHR0cDovL2NjYm4uMTBrd2l6YXJkLmNvbS94bWwvZmlsaW5nLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MjExODM0MSZkb2M9Mw==
|
|
|
Serologicals - SEC Filings
29, 2003 2002 ----------- -------- Cash and cash equivalents $21,146 $12,850 Accounts receivable 26,019 35,868 Inventory 29,889 26,305 Total assets 194,328 191,165 Total liabilities 21,148 20,795 Stockholders' equity 173,180 170,370 CONTACT: Serologicals Corporation, Atlanta Bud Ingalls, 678/728-2115 Craig Brown, 678/728-2117 or In-Site Communications Lisa Wilson, 212/759-3929 - --...
|
|
|
Serologicals - SEC Filings
20 Page 6 --- Previous Page -|- Next Page --- Our Company |- Investors |- Partners |- News & Events |- Contact Us |- For Job Seekers For Scientists |- Serologicals Worldwide |- FAQs Serologicals Corporation 2006 - About Serologicals Our Companies Products and Services Research Research Overview Enzymes and Assays Stem Cell Products Biomarkers & Multiplex Discovery Discovery Overview...
|
|
|
Serologicals - SEC Filings
29, 2003 2002 ----------- -------- Cash and cash equivalents $21,146 $12,850 Accounts receivable 26,019 35,868 Inventory 29,889 26,305 Total assets 194,328 191,165 Total liabilities 21,148 20,795 Stockholders' equity 173,180 170,370 CONTACT: Serologicals Corporation, Atlanta Bud Ingalls, 678/728-2115 Craig Brown, 678/728-2117 or In-Site Communications Lisa Wilson, 212/759-3929 Page 1...
|
|
|
Serologicals - SEC Filings
- xsideNav ul li.test { width:130px; background-image:url(/images/menu/right-Dblue.gif); background-repeat: no-repeat; background-position:right; } Overview Stock Information Corporate Governance FAQs Financial Information Financial Schedules #content { padding: 10px 15px 35px 5px;} #content table { font-size:12px; }.modGovTtl { font-size:13px; font-weight:bold; }.modGovSubTtl { font...
duplicates:
http://WWW.SEROLOGICALS.COM/investors.asp?c=113258&p=irol-secText&TEXT=aHR0cDovL2NjYm4uMTBrd2l6YXJkLmNvbS94bWwvZmlsaW5nLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MzQ0NDE5NiZkb2M9Mg==
|
|
|
Serologicals - SEC Filings
QuickLinks Serologicals Issues Correction For Computational Error - ---Previous Page -|- Next Page--- Our Company |- Investors |- Partners |- News & Events |- Contact Us |- For Job Seekers For Scientists |- Serologicals Worldwide |- FAQs Serologicals Corporation 2006 - About Serologicals Our Companies Products and Services Research Research Overview Enzymes and Assays Stem Cell...
|
|
|
Serologicals - SEC Filings
- xsideNav ul li.test { width:130px; background-image:url(/images/menu/right-Dblue.gif); background-repeat: no-repeat; background-position:right; } Overview Stock Information Corporate Governance FAQs Financial Information Financial Schedules #content { padding: 10px 15px 35px 5px;} #content table { font-size:12px; }.modGovTtl { font-size:13px; font-weight:bold; }.modGovSubTtl { font...
duplicates:
http://WWW.SEROLOGICALS.COM/investors.asp?c=113258&p=irol-secText&TEXT=aHR0cDovL2NjYm4uMTBrd2l6YXJkLmNvbS94bWwvZmlsaW5nLnhtbD9yZXBvPXRlbmsmaXBhZ2U9MTI0NzYxOSZkb2M9MQ==
|
|
|
Serologicals - SEC Filings
GROSS PROFIT Page 28 --- Previous Page -|- Next Page --- Our Company |- Investors |- Partners |- News & Events |- Contact Us |- For Job Seekers For Scientists |- Serologicals Worldwide |- FAQs Serologicals Corporation 2006 - About Serologicals Our Companies Products and Services Research Research Overview Enzymes and Assays Stem Cell Products Biomarkers & Multiplex Discovery...
|
|
|
Serologicals - SEC Filings
13.9% 9.6% 20.3% YEARS ENDED DECEMBER 31, 2000 AND DECEMBER 26, 1999 NET SALES Page 23 --- Previous Page -|- Next Page --- Our Company |- Investors |- Partners |- News & Events |- Contact Us |- For Job Seekers For Scientists |- Serologicals Worldwide |- FAQs Serologicals Corporation 2006 - About Serologicals Our Companies Products and Services Research Research Overview Enzymes and...
|
|
|
Serologicals - SEC Filings
The increase was primarily attributable to higher corporate expenses, including recruiting and other costs associated with the hiring of certain executives, increased 18 Page 18 --- Previous Page -|- Next Page --- Our Company |- Investors |- Partners |- News & Events |- Contact Us |- For Job Seekers For Scientists |- Serologicals Worldwide |- FAQs Serologicals Corporation 2006 -...
|
|
|
Serologicals - SEC Filings
Pizzo, III Chief Financial Officer (Principal Financial and Accounting Officer) 24 - ---Previous Page -|- Next Page--- Our Company |- Investors |- Partners |- News & Events |- Contact Us |- For Job Seekers For Scientists |- Serologicals Worldwide |- FAQs Serologicals Corporation 2006 - About Serologicals Our Companies Products and Services Research Research Overview Enzymes and...
|
|
|
Serologicals - Press Release
SOURCE: Serologicals Corporation Serologicals, Atlanta Bud Ingalls, 678-728-2115 Our Company |- Investors |- Partners |- News & Events |- Contact Us |- For Job Seekers For Scientists |- Serologicals Worldwide |- FAQs Serologicals Corporation 2006 - About Serologicals Our Companies Products and Services Research Research Overview Enzymes and Assays Stem Cell Products Biomarkers &...
|
|
|
Serologicals - Press Release
SOURCE: Serologicals Corporation Serologicals, Atlanta Bud Ingalls, 678-728-2115 Our Company |- Investors |- Partners |- News & Events |- Contact Us |- For Job Seekers For Scientists |- Serologicals Worldwide |- FAQs Serologicals Corporation 2006 - About Serologicals Our Companies Products and Services Research Research Overview Enzymes and Assays Stem Cell Products Biomarkers &...
|
|
|
Cell Imaging Protocols and Applications Guide
General Immunocytochemistry Protocol Materials Required: Anti-PARP p85 Fragment pAb ( Cat.# G7341 ) cells fixed on slides PBS blocking buffer (PBS/0.1% Tween A® 20 + 5% horse serum) donkey anti-rabbit biotin conjugate (Jackson Cat.# 711-065-152) or donkey anti-rabbit Cy A® 3 conjugate (Jackson Cat.# 711-165-152) H2O2 (if using biotin conjugate) DAB solution (if...
|
|
|
Cell Signaling Protocols and Applications Guide
Class IA PI3-Ks signal downstream of tyrosine kinases; class IB PI3-Ks signal downstream of G protein-coupled receptors (GPCRs; Vanhaesebroeck et al.
For additional information see Technical Bulletin # TB262 Materials Required: Anti-ACTIVE A® Qualified Donkey Anti-Rabbit IgG (H+L), HRP ( Cat.# V7951 ) or Donkey Anti-Rabbit IgG (H+L), AP ( Cat.# V7971 )...
|
|
|
Apoptosis Protocols and Applications Guide
General Immunocytochemistry Protocol Materials Required: Anti-PARP p85 Fragment pAb (Cat.# G7341) cells fixed on slides PBS blocking buffer (PBS/0.1% Tween A® 20 + 5% horse serum) donkey anti-rabbit biotin conjugate (Jackson Cat.# 711-065-152) or donkey anti-rabbit Cy A® 3 conjugate (Jackson Cat.# 711-165-152) H2O 2 (if using biotin conjugate) DAB solution (if...
|
